REG - Polarean Imaging PLC - Block Listing Six Monthly Return

Polarean ImagingAnnouncement

24/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250124:nRSX3364Ua&default-theme=true

RNS Number : 3364U  Polarean Imaging PLC  24 January 2025

Polarean Imaging Plc

("Polarean" or the "Company")

 

Block Listing Six Monthly Return

 

Polarean Imaging Plc (AIM: POLX), a commercial-stage medical device leader in
advanced Magnetic Resonance Imaging ("MRI") of lung function, today makes the
following notification pursuant to Schedule Six of the AIM Rules for Companies
regarding its existing block admission arrangements:

 

 Name of applicant:                                                                     Polarean Imaging Plc
 Name of scheme:                                                                        Polarean Share Option Plan
 Number and class of securities originally admitted:                                    8,000,000 ordinary shares of £0.00037 each
 Date of admission:                                                                     29 July 2021
 Period of return:                                         From:                        27 July 2024     To:              24 January 2025
 Balance of unallotted securities under scheme(s) from previous return:                 808,917
 Plus: The amount by which the block scheme(s) has been increased since the             0
 date of the last return (if any increase has been applied for):

 Less: Number of securities issued/allotted under scheme(s) during period (see          0
 LR3.5.7G):

 Equals: Balance under scheme(s) not yet issued/allotted at end of period:              808,917
 Total number of securities in issue at the end of the period                           1,207,032,781

 

 Name of contact:              Charles F. Osborne, Jr., Chief Financial Officer
 Telephone number of contact:  + 44 (0)20 7933 8780 or polarean@walbrookpr.com

 

Enquiries:

 

 Polarean Imaging plc                                     www.polarean.com (http://www.polarean.com) / www.polarean-ir.com
                                                          (http://www.polarean-ir.com)
 Christopher von Jako, Chief Executive Officer            Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)                 +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Walbrook PR        Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
                    (mailto:polarean@walbrookpr.com)
 Anna Dunphy /Phillip Marriage         Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

 

About Polarean (www.polarean.com (http://www.polarean.com) )

 

Polarean is a revenue-generating medical imaging technology company
revolutionizing pulmonary medicine through direct visualization of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimize lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarization science and has successfully developed the first and only
hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarization system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRPKBBQQBKDCDB